uniQure N.V. (NASDAQ:QURE) Given Consensus Rating of “Moderate Buy” by Brokerages

uniQure N.V. (NASDAQ:QURE) has received an average recommendation of “Moderate Buy” from the seventeen ratings firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating and ten have assigned a buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $42.8333.

Several analysts have weighed in on QURE shares. Wall Street Zen upgraded uniQure from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Cantor Fitzgerald reissued a “neutral” rating and issued a $9.00 price objective (down from $55.00) on shares of uniQure in a report on Monday, March 2nd. Leerink Partners reissued an “outperform” rating and issued a $35.00 price objective on shares of uniQure in a report on Monday, March 2nd. HC Wainwright decreased their price objective on uniQure from $70.00 to $50.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Finally, Mizuho raised uniQure from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $12.00 to $35.00 in a report on Wednesday, March 11th.

uniQure Stock Down 2.3%

uniQure stock opened at $24.19 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40. The business’s 50-day simple moving average is $19.20 and its two-hundred day simple moving average is $22.05. The company has a market cap of $1.53 billion, a PE ratio of -6.95 and a beta of 0.87. uniQure has a fifty-two week low of $8.73 and a fifty-two week high of $71.50.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.03. The business had revenue of $3.56 million for the quarter, compared to the consensus estimate of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. Equities analysts anticipate that uniQure will post -3.68 EPS for the current year.

Insider Buying and Selling

In other news, insider Jeannette Potts sold 3,412 shares of the business’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $30,912.72. Following the completion of the transaction, the insider owned 138,483 shares of the company’s stock, valued at $1,254,655.98. The trade was a 2.40% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Christian Klemt sold 12,000 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total transaction of $108,720.00. Following the sale, the chief financial officer directly owned 226,581 shares in the company, valued at $2,052,823.86. This trade represents a 5.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 94,396 shares of company stock worth $1,850,434. Corporate insiders own 4.79% of the company’s stock.

Institutional Trading of uniQure

A number of hedge funds have recently added to or reduced their stakes in the company. Jones Financial Companies Lllp boosted its holdings in uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after buying an additional 509 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in uniQure by 5.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock worth $243,000 after buying an additional 533 shares in the last quarter. Arizona State Retirement System boosted its holdings in uniQure by 6.0% during the fourth quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock worth $267,000 after buying an additional 627 shares in the last quarter. Ensign Peak Advisors Inc boosted its position in uniQure by 21.7% during the fourth quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock worth $87,000 after purchasing an additional 650 shares in the last quarter. Finally, FNY Investment Advisers LLC boosted its position in uniQure by 76.7% during the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 718 shares in the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.